Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Veracyte gets rights to NanoString's diagnostics

Executive Summary

NanoString Technologies Inc. licensed Veracyte Inc. exclusive global rights to develop and commercialize diagnostics on its nCounter FLEX analysis system. Veracyte also gets rights to NanoString’s 510(k)-cleared Prosigna breast cancer prognostic gene signature assay and LymphMark lymphoma subtyping test.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register